檢索結果 - Martin J. Edelman

Refine Results
  1. 1
    The Utility of Follow-up Testing After Curative Cancer Therapy A Critical Review and Economic Analysis

    The Utility of Follow-up Testing After Curative Cancer Therapy A Critical Review and Economic Analysis 由 Martin J. Edelman, Frederick J. Meyers, David Siegel

    出版 1997
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer

    50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer 由 Heather A. Wakelee, Karen Kelly, Martin J. Edelman

    出版 2014
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Population-Based Estimates of Survival Benefit Associated with Combined Modality Therapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer

    Population-Based Estimates of Survival Benefit Associated with Combined Modality Therapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer 由 Amy J. Davidoff, James F. Gardner, Brian Seal, Martin J. Edelman

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

    Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer 由 Amy J. Davidoff, Mei Jie Tang, Brian Seal, Martin J. Edelman

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy

    Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy 由 Jun Zhao, Z. Mark, Hening Ren, Zhenqiu Liu, Martin J. Edelman, Hong Pan, Li Mao

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies

    Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies 由 Amy J. Davidoff, Lisa D Gardner, Ilene H. Zuckerman, Franklin Hendrick, Xuehua Ke, Martin J. Edelman

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    A War on Two Fronts: Cancer Care in the Time of COVID-19

    A War on Two Fronts: Cancer Care in the Time of COVID-19 由 Alexander Kutikov, David S. Weinberg, Martin J. Edelman, Eric M. Horwitz, Robert G. Uzzo, Richard I. Fisher

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

    Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells 由 Minu K. Srivastava, Jacobus J. Bosch, James A. Thompson, Bruce R. Ksander, Martin J. Edelman, Suzanne Ostrand‐Rosenberg

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304

    CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304 由 Martin J. Edelman, Lydia Hodgson, Paula Rosenblatt, Robert H. Christenson, Everett E. Vokes, Xiaofei Wang, Robert A. Kratzke

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

    Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials 由 Primo N. Lara, Mary W. Redman, Karen Kelly, Martin J. Edelman, Stephen K. Williamson, John J. Crowley, David R. Gandara

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

    Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium 由 Robert Dreicer, Judith Manola, Bruce J. Roth, William A. See, Steven A. Kuross, Martin J. Edelman, Gary R. Hudes, George Wilding

    出版 2004
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

    Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-cen... 由 Bhavana Bhatnagar, Steven Gilmore, Olga Goloubeva, Colleen Pelser, Michelle Medeiros, Saranya Chumsri, Katherine H. R. Tkaczuk, Martin J. Edelman, Ting Bao

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Phase I Study of G3139, a <i>bcl-2</i> Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer

    Phase I Study of G3139, a <i>bcl-2</i> Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer 由 Charles M. Rudin, Mark Kozloff, Philip C. Hoffman, Martin J. Edelman, Robyn Karnauskas, R Tomek, Livia L. Szeto, Everett E. Vokes

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors

    Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors 由 Sanjeevani Arora, R. A. Velichinskii, Randy W. Lesh, Usman Ali, Michal Kubiak, Pranshu Bansal, Hossein Borghaei, Martin J. Edelman, Yanis Boumber

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  15. 15
    High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival

    High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival 由 King F. Kwong, Martin J. Edelman, Mohan Suntharalingam, Lindsay B. Cooper, Ziv Gamliel, W. Burrows, P Hausner, L. Austin Doyle, Mark J. Krasna

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    GP88 (progranulin): a novel tissue and circulating biomarker for non–small cell lung carcinoma

    GP88 (progranulin): a novel tissue and circulating biomarker for non–small cell lung carcinoma 由 Martin J. Edelman, Josephine Feliciano, Binbin Yue, P.A. Bejarano, Olga B. Ioffe, David Reisman, Douglas M. Hawkins, Qiwei Gai, David G. Hicks, Ginette Serrero

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias

    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias 由 Ken Shiozawa, Takeo Nakanishi, Ming Tan, Hong-Bin Fang, Wen-chyi Wang, Martin J. Edelman, David P. Carlton, Ivana Gojo, Edward A. Sausville, Douglas D. Ross

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung 由 David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy

    Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy 由 Katherine A. Scilla, Søren M. Bentzen, Vincent K. Lam, Pranshu Mohindra, Elizabeth Nichols, Melissa A.L. Vyfhuis, Neha Bhooshan, Steven J. Feigenberg, Martin J. Edelman, Josephine Feliciano

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

    Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy... 由 Jillian A. Moran, Daniel L. Adams, Martin J. Edelman, Pablo Lopez, Jianzhong He, Yawei Qiao, Ting Xu, Zhongxing Liao, Kirby P. Gardner, Cha‐Mei Tang, Steven H. Lin

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: